Guillain-Barré Syndrome
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (10)
Total enrollment: 407 patients across 10 trials
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome
Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
Single Dose Study of ANX005 in Healthy Volunteers
Related Jobs
Director, Quality Systems
Vice President, Medical Affairs-Neuroscience
Director, Procurement Strategic Contract Negotiator
Vice President, Clinical Development-Neuroscience
Vice President, Medical Affairs-Ophthalmology
Field Medical Director (MSL) – Ophthalmology (Central Plains Region)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.